Roche in take-over deal with GenMark Diagnostics

The US$1.8bn cash merger – US$ 24.05 per share –  is set to close in Q2/2021. The price represents a premium of approximately 43% to GenMark’s unaffected closing share price on February 10, 2021.

GenMark’s multiplex PCR panel testing portfolio will complement Roche’s current molecular diagnostics portfolio. According to Thomas Schinecker, CEO Roche Diagnostics, GenMarl’s panel testing "provides faster targeted therapeutic intervention, resulting in improved patient outcomes and reduced hospital stays."

Utilizing GenMark’s point-of-care eSensor detection technology, GenMark’s eSensor XT-8 and ePlex systems are designed to address a broad range of infectious disease testing needs, including respiratory, bloodstream and gastrointestinal infections.